Surgical Science Sweden
130
SEK
-1,52 %
Mindre end 1K følgere
SUS
First North Stockholm
Medical Equipment & Services
Health Care
Overview
Finansielt overblik og estimater
Ownership
-1,52%
-26,76%
-16,61%
-13,85%
+7,08%
-7,54%
-30,85%
+167,49%
+1.030,43%
Surgical Science Sweden is a medical technology company. The company develops VR simulators in surgery. The simulators consist of both hardware and software used in training and personal development by surgeons. The hardware simulates various surgical procedures, with mainly use in peephole surgery and endoscopy. The vision is to strengthen the competence in surgery and create conditions for better treatments. The company is headquartered in Gothenburg.
Læs mereMarkedsværdi
6,63 mia. SEK
Aktieomsætning
54,45 mio. SEK
Omsætning
884,09 mio.
EBIT %
16,32 %
P/E
50,39
Udbytteafkast, %
-
Finanskalender
14.5
2025
Delårsrapport Q1'25
15.5
2025
Generalforsamling '25
21.8
2025
Delårsrapport Q2'25
Alle
Selskabspræsentationer
Selskabsmeddelelser
ViserAlle indholdstyper

Surgical Science Sweden, Audiocast with teleconference, Q4'24
Year-end report 2024: STRONG END TO THE YEAR
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Scheme of Arrangement Effective in relation to the Recommended Offer to Acquire Intelligent Ultrasound
Results of Shareholder Meetings in relation to the Recommended Offer to Acquire Intelligent Ultrasound
Conference call regarding Year-end report 2024
Surgical Science wins a procurement contract in Southeast Asia amounting to SEK 52 million – new product and new customer group
Proposal for election of the board of Surgical Science Sweden AB (publ)
Surgical Science is transitioning to a fully subscription-based revenue model with Intuitive and all da Vinci 5* systems will be equipped with Surgical Science simulation software
Publication of Scheme Document in relation to the Recommended Offer to Acquire Intelligent Ultrasound

Surgical Science Sweden, Audiocast with teleconference, Press Conference, 2024
Surgical Science Announces Recommended Offer to Acquire Intelligent Ultrasound
Redeye: Surgical Science Q3 2024 - Sequential improvements continue

Surgical Science Sweden, Audiocast with teleconference, Q3'24
Interim report January – September 2024: 12% CURRENCY-NEUTRAL INCREASE IN SALES
Conference call regarding interim report Q3
Nomination Committee of Surgical Science Sweden AB (publ)
Tom Englund takes over as the new CEO of Surgical Science
Redeye: Surgical Science Q2 2024 - Solid sequential recovery, decent outlook
